02.27.25 -- How Do We Categorize CDMOs?

Join this live webinar to learn about the journey of a biologic drug from pre-clinical to commercial release. SGS’s experts will share their extensive knowledge of testing required and ways to overcome challenges encountered throughout the various stages of the drug development process. Click here to learn more.

Manufacturing ADCs is inherently more complex than other biologic drug products. Let's explore some of the key issues, including aggregation, solubility, and thermal instability.

Choosing the right containers and materials is critical. Two risk-based test methodologies help to select the optimum closure materials and correct syringe silicone level at the early phase of drug development.

No two journeys through the drug pipeline are the same; the ability to leverage a variety of approaches for different products is what sets one lean biotech company apart from the others.

Explore how one organization built upon 15+ years of experience and an extensive knowledge base of biologics manufacturing to establish commercial-scale ADC manufacturing capabilities.

It is essential for biopharma companies to stay up to date on the future of CDMOs. Read about three key trends that are helping shape the CDMO industry.

Review the essential phases of the lyophilization cycle—freezing, primary drying, and secondary drying—and critical success factors to achieve optimal product quality and stability.

Gain a deeper understanding of current directives and metrics to equip your team with the knowledge necessary to navigate the evolving landscape of sustainability.

Recognizing what it takes to complete technology transfers effectively and efficiently is crucial to selecting the best partner for your project and product needs.

Consider this manufacturing platform integrating perfusion bioreactors, continuous product capture, low pH viral inactivation, polishing, viral filtration, and formulation steps.

When choosing between protein expression formats such as transient versus stable pools, considerations include speed, cost, titre, and product quality.

Equipped with advanced robotics, our automated fill line is specially designed to maximize product yield while minimizing the risks associated with operator intervention.

From the production floor to the shipping door, your unique clinical or commercial requirements will be fulfilled at each step of the process.

Leverage robust development strategies and enable an optimized process for mAb development and manufacturing, efficiency and speed with exceptional quality, and high titers.

As pressure to accelerate timelines mounts, finding a CDMO committed to increasing capacity and optimizing processes with innovative technologies is key for adding efficiency.